Pneumococcal 21-Valent Conjugate Vaccine clinical trials
Also written PCV21.
Its developmentBy Merck and Sanofi, step by step18 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Pneumococcal 21-Valent Conjugate Vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Pneumococcal 21-Valent Conjugate Vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Jun 2024 · CAPVAXIVE · BLA 125814 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2022 (6)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 18 · Other 1
Merck Sharp & Dohme LLC (11) · Sanofi (5) · Sanofi Pasteur, a Sanofi Company (2) · VA Sierra Nevada Health Care System (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8, 7 in phase 3
Studies that test Pneumococcal 21-Valent Conjugate Vaccine, phase 3 first.
- Dec 2026Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and AdolescentsPhase 3 · Sanofi Pasteur, a Sanofi Company
- Jan 2027Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseasePhase 3 · Sanofi
- May 2027Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgePhase 3 · Sanofi Pasteur, a Sanofi Company
- Jun 2027Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgePhase 3 · Sanofi
- Aug 2027Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgePhase 3 · Sanofi
- Sep 2027Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgePhase 3 · Sanofi
- Oct 2027Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgePhase 3 · Sanofi
- Jan 2027Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly VeteransPhase 4 · VA Sierra Nevada Health Care System
Studies
Open first, then newest update. How each study uses Pneumococcal 21-Valent Conjugate Vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 19
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgeRecruitingPhase 3SanofiNCT07348692Written as PCV21 vaccine
- Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseRecruitingPhase 3SanofiNCT07247188Written as PCV21
- Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly VeteransNot yet recruitingPhase 4VA Sierra Nevada Health Care SystemNCT06271681Written as 21-valent pneumococcal conjugate vaccine
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3Sanofi Pasteur, a Sanofi CompanyNCT06736041Written as PCV21 vaccine
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824194Written as PCV21 vaccine
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)CompletedPhase 3Merck Sharp & Dohme LLCNCT06177912Written as V116
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)CompletedPhase 3Merck Sharp & Dohme LLCNCT05696080Written as V116
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06975878Written as PCV21 vaccine
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)CompletedPhase 3Merck Sharp & Dohme LLCNCT05569954Written as V116
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824181Written as PCV21 vaccine
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)CompletedPhase 3Merck Sharp & Dohme LLCNCT05393037Written as V116
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)CompletedPhase 3Merck Sharp & Dohme LLCNCT05526716Written as V116
- Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and AdolescentsActive, not recruitingPhase 3Sanofi Pasteur, a Sanofi CompanyNCT06838000Written as PCV21
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)CompletedPhase 3Merck Sharp & Dohme LLCNCT05425732Written as V116
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)CompletedPhase 3Merck Sharp & Dohme LLCNCT05420961Written as V116
- Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)CompletedPhase 3Merck Sharp & Dohme LLCNCT05633992Written as V116
- A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)CompletedPhase 3Merck Sharp & Dohme LLCNCT05464420Written as V116
- Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT04665050Written as V116
- A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04168190Written as V116